| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 59.47 | 0.14 (+0.24%) | 37.52 - 60.20 | 707.5 thousand |
Market data as of 4:00PM 05/22/13. Quotes are delayed by at least 15 min.
| Open | 59.70 |
|---|---|
| Previous Close | 59.33 |
| Day's Range | 58.83 - 60.00 |
| Market Cap | 3.6B |
| Avg Volume (10 Day) | 696.6K |
| Price/Earnings (Trailing 12 Mo.) | 49.0x |
| Earnings Per Share (Trailing 12 Mo.) | 1.21 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Salix Pharmaceuticals Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis in Two Pivotal Phase 3 Studies
Business Wire - Wednesday 05/22/2013 7:00 AM ET
Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013
Business Wire - Friday 05/17/2013 7:00 AM ET
Salix Pharmaceuticals Reports 1Q2013 Results
Business Wire - Thursday 05/09/2013 4:01 PM ET
Salix Pharmaceuticals to Present at BofA Merrill Lynch 2013 Health Care Conference
Business Wire - Tuesday 05/07/2013 7:00 AM ET
Salix Pharmaceuticals Announces 1Q2013 Financial Results Conference Call and Webcast
Business Wire - Thursday 04/25/2013 7:00 AM ET
| SLXP | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 26.61% | |
| Net Income Growth (1yr) | -20.95% | |
| Total Debt/Equity | 1.67 | |
| LT Debt/Equity | 1.67 | |
| Earnings Yield | 2.04% | |
| Price/Sales | 4.74 |
| Company | Last | Change |
|---|---|---|
| Akorn Inc | 14.55 | -1.89% |
| Momenta Pharmaceuticals Inc | 13.26 | +1.38% |
| Ligand Pharmaceuticals Inc | 27.38 | -1.30% |
| Sagent Pharmaceuticals Inc | 17.95 | +3.70% |
| Avanir Pharmaceuticals Inc | 3.25 | -0.61% |
Data is delayed by at least 15 min.